Sequencing the Available T Cell– Engaging Therapies, and the Role of Bridging/Holding Therapy in RRMM

Sequencing the Available T Cell– Engaging Therapies, and the Role of Bridging/Holding Therapy in RRMM

Panelists discuss how effective sequencing and bridging strategies for T-cell engaging therapies in (relapsed/refractory multiple myeloma (RRMM) rely on using chimeric antigen receptor T-cell therapy (CAR T) first when feasible, while carefully selecting bridging treatments—such as nonoverlapping bispecifics or selinexor regimens—to manage disease without compromising CAR T readiness or long-term immune function.

The new therapy reduced cancer in 81% of patients and achieved complete remission in 52% of them, experiencing a lasting remission of two years or more. The findings, led by researchers from the Perelman School of Medicine at the University of Pennsylvania, have just been published in the New England Journal of Medicine. Although CAR-T cell therapy (a personalized form of cancer immunotherapy developed successfully for the first time by Dr. Carl…

Hematologic, Lymphatic Risks of CAR-T Therapy Revealed

In recent years, chimeric antigen receptor T-cell therapy, commonly known as CAR-T therapy, has revolutionized the field of oncology, offering hope for patients with refractory or relapsed hematologic malignancies. Despite its transformative potential, this groundbreaking immunotherapy is not without significant risks. New insights emerging from a comprehensive pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) now reve…